Literature DB >> 31445738

Nivolumab-Induced Secondary Sclerosing Cholangitis with Deterioration Despite Immunosuppression.

Brady Anderson1, David E Dawe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31445738     DOI： 10.1016/j.jtho.2019.04.023

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

Review 1.  Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings.

Authors:  Ryota Nakano; Hideyuki Shiomi; Aoi Fujiwara; Kohei Yoshihara; Ryota Yoshioka; Shoki Kawata; Shogo Ota; Yukihisa Yuri; Tomoyuki Takashima; Nobuhiro Aizawa; Naoto Ikeda; Takashi Nishimura; Hirayuki Enomoto; Hiroko Iijima
Journal:  Healthcare (Basel)       Date:  2022-04-20

2.  Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.

Authors:  Borui Pi; Jin Wang; Yifan Tong; Qiao Yang; Fangfang Lv; Yunsong Yu
Journal:  Eur J Gastroenterol Hepatol       Date:  2021-12-01       Impact factor: 2.586

3.  Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient.

Authors:  Zhuo Zhang; Ling Xu; Naishan Qin; Jixin Zhang; Qian Xiang; Qian Liu; Yuanjia Cheng; Yuge Bai; Qianxin Liu; Yinhua Liu; Xuening Duan; Yimin Cui
Journal:  Thorac Cancer       Date:  2021-05-06       Impact factor: 3.500
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.